| Year |
Citation |
Score |
| 2020 |
Röhm S, Schröder M, Dwyer JE, Widdowson CS, Chaikuad A, Berger BT, Joerger AC, Krämer A, Harbig J, Dauch D, Kudolo M, Laufer S, Bagley MC, Knapp S. Selective targeting of the αC and DFG-out pocket in p38 MAPK. European Journal of Medicinal Chemistry. 208: 112721. PMID 33035818 DOI: 10.1016/J.Ejmech.2020.112721 |
0.344 |
|
| 2020 |
Laufkötter O, Laufer S, Bajorath J. Kinase inhibitor data set for systematic analysis of representative kinases across the human kinome. Data in Brief. 32: 106189. PMID 32904416 DOI: 10.1016/J.Dib.2020.106189 |
0.339 |
|
| 2020 |
Laufkötter O, Laufer S, Bajorath J. Identifying representative kinases for inhibitor evaluation via systematic analysis of compound-based target relationships. European Journal of Medicinal Chemistry. 204: 112641. PMID 32745818 DOI: 10.1016/J.Ejmech.2020.112641 |
0.352 |
|
| 2020 |
Laufer S, Briner K, Bajorath J, Georg GI, Wang S. New Horizons in Drug Discovery - Understanding and Advancing Kinase Inhibitors. Journal of Medicinal Chemistry. PMID 32668159 DOI: 10.1021/Acs.Jmedchem.0C01136 |
0.306 |
|
| 2020 |
Scior T, Abdallah HH, Salvador-Atonal K, Laufer S. Dapsone is not a Pharmacodynamic Lead Compound for its Aryl Derivatives. Current Computer-Aided Drug Design. 16: 327-339. PMID 32507104 DOI: 10.2174/1573409915666191010104527 |
0.309 |
|
| 2020 |
Cianni L, Lemke C, Gilberg E, Feldmann C, Rosini F, Rocho FDR, Ribeiro JFR, Tezuka DY, Lopes CD, de Albuquerque S, Bajorath J, Laufer S, Leitão A, Gütschow M, Montanari CA. Mapping the S1 and S1' subsites of cysteine proteases with new dipeptidyl nitrile inhibitors as trypanocidal agents. Plos Neglected Tropical Diseases. 14: e0007755. PMID 32163418 DOI: 10.1371/Journal.Pntd.0007755 |
0.359 |
|
| 2019 |
González-Medina M, Miljković F, Haase GS, Drueckes P, Trappe J, Laufer S, Bajorath J. Promiscuity analysis of a kinase panel screen with designated p38 alpha inhibitors. European Journal of Medicinal Chemistry. 187: 112004. PMID 31881458 DOI: 10.1016/J.Ejmech.2019.112004 |
0.361 |
|
| 2019 |
Röhm S, Berger BT, Schröder M, Chaikuad A, Winkel R, Hekking KFW, Benningshof JJC, Mueller G, Tesch R, Kudolo M, Forster M, Laufer SA, Knapp S. A fast iterative synthetic approach towards the identification of novel highly selective p38 MAP kinase inhibitors. Journal of Medicinal Chemistry. PMID 31702918 DOI: 10.1021/Acs.Jmedchem.9B01227 |
0.364 |
|
| 2019 |
Guenthoer P, Fuchs K, Reischl G, Quintanilla-Martinez L, Gonzalez-Menendez I, Laufer S, Pichler BJ, Kneilling M. Evaluation of the therapeutic potential of the selective p38 MAPK inhibitor Skepinone-L and the dual p38/JNK 3 inhibitor LN 950 in experimental K/BxN serum transfer arthritis. Inflammopharmacology. PMID 31037574 DOI: 10.1007/S10787-019-00593-6 |
0.302 |
|
| 2019 |
do Amaral DN, Lategahn J, Fokoue HH, da Silva EMB, Sant'Anna CMR, Rauh D, Barreiro EJ, Laufer S, Lima LM. A novel scaffold for EGFR inhibition: Introducing N-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide derivatives. Scientific Reports. 9: 14. PMID 30626888 DOI: 10.1038/S41598-018-36846-7 |
0.318 |
|
| 2019 |
Stoll S, Bitencourt S, Laufer S, Inês Goettert M. Myricetin inhibits panel of kinases implicated in tumorigenesis. Basic & Clinical Pharmacology & Toxicology. 125: 3-7. PMID 30624861 DOI: 10.1111/Bcpt.13201 |
0.368 |
|
| 2019 |
Günther M, Laux J, Laufer S. Synthesis and structure‑activity‑relationship of 3,4‑Diaryl‑1H‑pyrrolo[2,3‑b]pyridines as irreversible Inhibitors of mutant EGFR‑L858R/T790M. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 128: 91-96. PMID 30471411 DOI: 10.1016/J.Ejps.2018.11.021 |
0.324 |
|
| 2019 |
El-Gokha A, Ansideri F, Andreev S, Schollmeyer D, Laufer S, Koch P. N1-{4-[2-(Methylthio)-1H-imidazol-5-yl]pyridin-2-yl}benzene-1,4-diamine Molbank. 2019. DOI: 10.3390/M1048 |
0.358 |
|
| 2018 |
Koch P, Laufer S. Special Issue: Kinase inhibitors. Molecules (Basel, Switzerland). 23. PMID 30037125 DOI: 10.3390/Molecules23071818 |
0.309 |
|
| 2018 |
Vuaroqueaux V, Kelter G, Hendriks HR, Laufer S, Fiebig H. Abstract B167: KRAS gene mutations are associated with tumor resistance toward the LN1222/AD736 p38 inhibitor Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B167 |
0.313 |
|
| 2017 |
Heider F, Haun U, Döring E, Kudolo M, Sessler C, Albrecht W, Laufer S, Koch P. From 2-Alkylsulfanylimidazoles to 2-Alkylimidazoles: An Approach towards Metabolically More Stable p38α MAP Kinase Inhibitors. Molecules (Basel, Switzerland). 22. PMID 29036906 DOI: 10.3390/Molecules22101729 |
0.363 |
|
| 2017 |
Drewry DH, Wells CI, Andrews DM, Angell R, Al-Ali H, Axtman AD, Capuzzi SJ, Elkins JM, Ettmayer P, Frederiksen M, Gileadi O, Gray N, Hooper A, Knapp S, Laufer S, et al. Progress towards a public chemogenomic set for protein kinases and a call for contributions. Plos One. 12: e0181585. PMID 28767711 DOI: 10.1371/Journal.Pone.0181585 |
0.313 |
|
| 2017 |
Kulkarni R, Mitkari U, Achaiah G, Laufer S, Bikshapti DVRN, Chandrashekar VM, Gurav PB, Joshi SJ, Chipade VD. Substituted benzamides from antiinflammatory and p38 kinase inhibitors to antitubercular activity: design, synthesis and screening. Mini Reviews in Medicinal Chemistry. PMID 28685700 DOI: 10.2174/1389557517666170707105416 |
0.389 |
|
| 2017 |
Günther M, Lategahn J, Juchum M, Doering E, Keul M, Engel J, Tumbrink HL, Rauh D, Laufer SA. Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site. Journal of Medicinal Chemistry. PMID 28603991 DOI: 10.1021/Acs.Jmedchem.7B00316 |
0.327 |
|
| 2017 |
Leestemaker Y, de Jong A, Witting KF, Penning R, Schuurman K, Rodenko B, Zaal EA, van de Kooij B, Laufer S, Heck AJR, Borst J, Scheper W, Berkers CR, Ovaa H. Proteasome Activation by Small Molecules. Cell Chemical Biology. PMID 28552582 DOI: 10.1016/J.Chembiol.2017.05.010 |
0.349 |
|
| 2017 |
Juchum M, Günther M, Döring E, Sievers-Engler A, Lämmerhofer M, Laufer S. Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping. Journal of Medicinal Chemistry. 60: 4636-4656. PMID 28482151 DOI: 10.1021/Acs.Jmedchem.7B00178 |
0.34 |
|
| 2017 |
Wentsch HK, Walter NM, Bührmann M, Mayer-Wrangowski S, Rauh D, Zaman GJ, Willemsen-Seegers N, Buijsman RC, Henning M, Dauch D, Zender L, Laufer S. Optimized Target Residence Time: Type I1/2 Inhibitors for p38α MAP Kinase with Improved Binding Kinetics through Direct Interaction with the R-Spine. Angewandte Chemie (International Ed. in English). PMID 28397331 DOI: 10.1002/Anie.201701185 |
0.336 |
|
| 2016 |
Cheng F, Twardowski L, Fehr S, Aner C, Schaeffeler E, Joos T, Knorpp T, Dorweiler B, Laufer S, Schwab M, Torzewski M. Selective p38α MAP kinase/MAPK14 inhibition in enzymatically-modified LDL-stimulated human monocytes: implications for atherosclerosis. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. PMID 27871059 DOI: 10.1096/Fj.201600669R |
0.346 |
|
| 2016 |
Ostrovskyi D, Rumpf T, Eib J, Lumbroso A, Slynko I, Klaeger S, Heinzlmeir S, Forster M, Gehringer M, Pfaffenrot E, Bauer SM, Schmidtkunz K, Wenzler S, Metzger E, Kuster B, ... Laufer S, et al. Tofacitinib and analogs as inhibitors of the histone kinase PRK1 (PKN1). Future Medicinal Chemistry. PMID 27572962 DOI: 10.4155/Fmc-2016-0132 |
0.322 |
|
| 2016 |
Bauer SM, Kubiak JM, Rothbauer U, Laufer S. From Enzyme to Whole Blood: Sequential Screening Procedure for Identification and Evaluation of p38 MAPK Inhibitors. Methods in Molecular Biology (Clifton, N.J.). 1360: 123-48. PMID 26501907 DOI: 10.1007/978-1-4939-3073-9_10 |
0.378 |
|
| 2016 |
Thaher BA, Schollmeyer D, Laufer S. Poly[[tetramethanolbis[4-oxo-3-(pyridin-4-yl)-1-(2,4,6-trichlorophenyl)-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-olato]disodium]–diethyl ether–methanol (1/1/2)] Iucrdata. 1. DOI: 10.1107/S2414314616010816 |
0.314 |
|
| 2015 |
Fehr S, Unger A, Schaeffeler E, Herrmann S, Laufer S, Schwab M, Albrecht W. Impact of p38 MAP Kinase Inhibitors on LPS-Induced Release of TNF-α in Whole Blood and Primary Cells from Different Species. Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology. 36: 2237-49. PMID 26279429 DOI: 10.1159/000430188 |
0.345 |
|
| 2015 |
von Koschitzky I, Gerhardt H, Lämmerhofer M, Kohout M, Gehringer M, Laufer S, Pink M, Schmitz-Spanke S, Strube C, Kaiser A. New insights into novel inhibitors against deoxyhypusine hydroxylase from plasmodium falciparum: compounds with an iron chelating potential. Amino Acids. 47: 1155-66. PMID 25715757 DOI: 10.1007/S00726-015-1943-Z |
0.34 |
|
| 2015 |
Laufer S. New Frontiers in Kinases: Second Generation Inhibitors-Going beyond Cancer. Acs Medicinal Chemistry Letters. 6: 1. PMID 25589939 DOI: 10.1021/Ml500527E |
0.305 |
|
| 2015 |
Ribeiro D, Freitas M, Tomé SM, Silva AM, Laufer S, Lima JL, Fernandes E. Flavonoids inhibit COX-1 and COX-2 enzymes and cytokine/chemokine production in human whole blood. Inflammation. 38: 858-70. PMID 25139581 DOI: 10.1007/S10753-014-9995-X |
0.325 |
|
| 2014 |
El-Said OM, Hamed MM, Laufer S, Abadi AH. Design and synthesis of novel quinazoline derivatives and their evaluation as PI3Ks inhibitors. Chemical & Pharmaceutical Bulletin. 62: 1166-72. PMID 25450624 DOI: 10.1248/Cpb.C14-00560 |
0.379 |
|
| 2014 |
Anton R, Bauer SM, Keck PR, Laufer S, Rothbauer U. A p38 substrate-specific MK2-EGFP translocation assay for identification and validation of new p38 inhibitors in living cells: a comprising alternative for acquisition of cellular p38 inhibition data. Plos One. 9: e95641. PMID 24743242 DOI: 10.1371/Journal.Pone.0095641 |
0.378 |
|
| 2014 |
Ahmed NS, Elgendy M, Laufer S, Abadi AH. Discovery of a novel series of tetrahydro-β-carbolines inducing autophagic cell death in human metastatic melanoma. Archiv Der Pharmazie. 347: 398-406. PMID 24652680 DOI: 10.1002/Ardp.201300437 |
0.312 |
|
| 2014 |
Laufer S, Bajorath J. New frontiers in kinases: second generation inhibitors. Journal of Medicinal Chemistry. 57: 2167-8. PMID 24606189 DOI: 10.1021/Jm500195X |
0.311 |
|
| 2014 |
Koch DA, Silva RB, de Souza AH, Leite CE, Nicoletti NF, Campos MM, Laufer S, Morrone FB. Efficacy and gastrointestinal tolerability of ML3403, a selective inhibitor of p38 MAP kinase and CBS-3595, a dual inhibitor of p38 MAP kinase and phosphodiesterase 4 in CFA-induced arthritis in rats. Rheumatology (Oxford, England). 53: 425-32. PMID 24241037 DOI: 10.1093/Rheumatology/Ket369 |
0.352 |
|
| 2013 |
Ramer R, Walther U, Borchert P, Laufer S, Linnebacher M, Hinz B. Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib. Journal of Lipid Research. 54: 3116-29. PMID 23943857 DOI: 10.1194/Jlr.M042283 |
0.314 |
|
| 2013 |
Atemnkeng VA, Pink M, Schmitz-Spanke S, Wu XJ, Dong LL, Zhao KH, May C, Laufer S, Langer B, Kaiser A. Deoxyhypusine hydroxylase from Plasmodium vivax, the neglected human malaria parasite: molecular cloning, expression and specific inhibition by the 5-LOX inhibitor zileuton. Plos One. 8: e58318. PMID 23505486 DOI: 10.1371/Journal.Pone.0058318 |
0.308 |
|
| 2013 |
Kulkarni RG, Laufer S, Mangannavar C, Garlapati A. Design, synthesis and characterization of N', N"-diaryl ureas as p38 kinase inhibitors. Medicinal Chemistry (ShāRiqah (United Arab Emirates)). 9: 213-21. PMID 22946566 DOI: 10.2174/1573406411309020006 |
0.391 |
|
| 2012 |
Elkady M, Keck PRWEF, Schollmeyer D, Laufer S. 3-(4-Bromo-phen-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde. Acta Crystallographica Section E-Structure Reports Online. 68. PMID 23476224 DOI: 10.1107/S1600536812046752 |
0.322 |
|
| 2012 |
Elkady M, Keck PRWEF, Schollmeyer D, Laufer S. 2-[5-Bromo-1-(3-chloro-benz-yl)-2-methyl-1H-indol-3-yl]acetic acid. Acta Crystallographica Section E-Structure Reports Online. 68. PMID 23476223 DOI: 10.1107/S1600536812046740 |
0.33 |
|
| 2012 |
Dimova D, Iyer P, Vogt M, Totzke F, Kubbutat MHG, Schächtele C, Laufer S, Bajorath J. Assessing the target differentiation potential of imidazole-based protein kinase inhibitors. Journal of Medicinal Chemistry. 55: 11067-11071. PMID 23210446 DOI: 10.1021/Jm3014508 |
0.362 |
|
| 2012 |
Abu Thaher B, Koch P, Schollmeyer D, Laufer S. 4-(4-Fluoro-phen-yl)-3-(pyridin-4-yl)-1-(2,4,6-trichloro-phen-yl)-1H-pyrazol-5-amine. Acta Crystallographica. Section E, Structure Reports Online. 68: o2603. PMID 22969508 DOI: 10.1107/S1600536812033569 |
0.321 |
|
| 2012 |
Selig R, Goettert M, Schattel V, Schollmeyer D, Albrecht W, Laufer S. A Frozen Analogue Approach to Aminopyridinylimidazoles Leading to Novel and Promising p38 MAP Kinase Inhibitors Journal of Medicinal Chemistry. 55: 8429-8439. PMID 22951114 DOI: 10.1021/Jm300852W |
0.35 |
|
| 2012 |
De Simone R, Bruno I, Riccio R, Stadler K, Bauer J, Schaible AM, Laufer S, Werz O. Identification of new γ-hydroxybutenolides that preferentially inhibit the activity of mPGES-1. Bioorganic & Medicinal Chemistry. 20: 5012-6. PMID 22795900 DOI: 10.1016/J.Bmc.2012.06.032 |
0.343 |
|
| 2012 |
Abu Thaher B, Koch P, Schollmeyer D, Laufer S. 4-[5-Amino-4-(4-fluoro-phen-yl)-3-(pyridin-4-yl)-1H-pyrazol-1-yl]benzo-nitrile. Acta Crystallographica. Section E, Structure Reports Online. 68: o935. PMID 22589998 DOI: 10.1107/S160053681200877X |
0.331 |
|
| 2012 |
Fronza M, Lamy E, Günther S, Heinzmann B, Laufer S, Merfort I. Abietane diterpenes induce cytotoxic effects in human pancreatic cancer cell line MIA PaCa-2 through different modes of action Phytochemistry. 78: 107-119. PMID 22436445 DOI: 10.1016/J.Phytochem.2012.02.015 |
0.306 |
|
| 2012 |
Abu Thaher B, Koch P, Schollmeyer D, Laufer S. Ethyl 5-amino-3-(pyridin-4-yl)-1-(2,4,6-tri-chloro-phen-yl)-1H-pyrazole-4-carb-oxyl-ate dimethyl sulfoxide hemisolvate. Acta Crystallographica. Section E, Structure Reports Online. 68: o917-8. PMID 22412761 DOI: 10.1107/S1600536812008264 |
0.322 |
|
| 2012 |
Abu Thaher B, Koch P, Schollmeyer D, Laufer S. 4-(4-Fluoro-phen-yl)-1-(4-nitro-phen-yl)-3-(pyridin-4-yl)-1H-pyrazol-5-amine. Acta Crystallographica. Section E, Structure Reports Online. 68: o633. PMID 22412538 DOI: 10.1107/S1600536812004102 |
0.333 |
|
| 2012 |
Abu Thaher B, Koch P, Schollmeyer D, Laufer S. 4-(4-Fluoro-phen-yl)-1-phenyl-3-(pyridin-4-yl)-1H-pyrazol-5-amine. Acta Crystallographica. Section E, Structure Reports Online. 68: o632. PMID 22412537 DOI: 10.1107/S1600536812004096 |
0.333 |
|
| 2012 |
Tavolari S, Munarini A, Storci G, Laufer S, Chieco P, Guarnieri T. The decrease of cell membrane fluidity by the non-steroidal anti-inflammatory drug Licofelone inhibits epidermal growth factor receptor signalling and triggers apoptosis in HCA-7 colon cancer cells. Cancer Letters. 321: 187-194. PMID 22343320 DOI: 10.1016/J.Canlet.2012.02.003 |
0.316 |
|
| 2012 |
Graziosi L, Mencarelli A, Santorelli C, Renga B, Cipriani S, Cavazzoni E, Palladino G, Laufer S, Burnet M, Donini A, Fiorucci S. Mechanistic role of p38 MAPK in gastric cancer dissemination in a rodent model peritoneal metastasis. European Journal of Pharmacology. 674: 143-52. PMID 22119383 DOI: 10.1016/J.Ejphar.2011.11.015 |
0.308 |
|
| 2011 |
Fronza M, Murillo R, Ślusarczyk S, Adams M, Hamburger M, Heinzmann B, Laufer S, Merfort I. In vitro cytotoxic activity of abietane diterpenes from Peltodon longipes as well as Salvia miltiorrhiza and Salvia sahendica. Bioorganic & Medicinal Chemistry. 19: 4876-4881. PMID 21775156 DOI: 10.1016/J.Bmc.2011.06.067 |
0.306 |
|
| 2011 |
Ahmed NS, Gary BD, Tinsley HN, Piazza GA, Laufer S, Abadi AH. Design, synthesis and structure-activity relationship of functionalized tetrahydro-β-carboline derivatives as novel PDE5 inhibitors. Archiv Der Pharmazie. 344: 149-57. PMID 21384413 DOI: 10.1002/Ardp.201000236 |
0.364 |
|
| 2011 |
Malik N, Lees M, Moradi V, Laufer S, Schett G, Burnet M, Seed M. Transient exposure of macrophages to P38 map kinase inhibition conditions cell responses through MAPK activated protein kinase-2 regulation Annals of the Rheumatic Diseases. 70. DOI: 10.1136/Ard.2010.148965.11 |
0.348 |
|
| 2011 |
Selig R, Schattel V, Goettert M, Schollmeyer D, Albrecht W, Laufer S. Conformational effects on potency of thioimidazoles and dihydrothiazolines Medchemcomm. 2: 261-269. DOI: 10.1039/C0Md00228C |
0.36 |
|
| 2010 |
Koch P, Schollmeyer D, Laufer S. 5-(4-Fluoro-phen-yl)-4-(4-pyrid-yl)-1,3-oxazol-2-amine. Acta Crystallographica. Section E, Structure Reports Online. 66: o917. PMID 21580727 DOI: 10.1107/S1600536810009189 |
0.313 |
|
| 2010 |
Selig R, Schollmeyer D, Schlosser J, Albrecht W, Laufer S. 7-[4-(4-Fluorophenyl)-2-methylsulfanyl-1H-imidazol-5-yl]tetrazolo[1,5-a]pyridine Acta Crystallographica Section E-Structure Reports Online. 66. PMID 21579866 DOI: 10.1107/S1600536810002680 |
0.312 |
|
| 2010 |
Goettert M, Schattel V, Koch P, Merfort I, Laufer S. Biological evaluation and structural determinants of p38α mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids. Chembiochem : a European Journal of Chemical Biology. 11: 2579-88. PMID 21108268 DOI: 10.1002/Cbic.201000487 |
0.391 |
|
| 2010 |
Ahmed NS, Gary BD, Piazza GA, Tinsley HN, Laufer S, Abadi AH. A novel access to arylated and heteroarylated beta-carboline based PDE5 inhibitors. Medicinal Chemistry (ShāRiqah (United Arab Emirates)). 6: 374-87. PMID 21054274 DOI: 10.2174/157340610793563992 |
0.354 |
|
| 2010 |
Laufer S, Hauser D, Stegmiller T, Bracht C, Ruff K, Schattel V, Albrecht W, Koch P. Tri- and tetrasubstituted imidazoles as p38α mitogen-activated protein kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 20: 6671-5. PMID 20934337 DOI: 10.1016/J.Bmcl.2010.09.012 |
0.38 |
|
| 2010 |
Laufer S, Luik S. Different methods for testing potential cyclooxygenase-1 and cyclooxygenase-2 inhibitors Methods in Molecular Biology (Clifton, N.J.). 644: 91-116. PMID 20645167 DOI: 10.1007/978-1-59745-364-6_8 |
0.33 |
|
| 2010 |
Serry AM, Luik S, Laufer S, Abadi AH. One-pot synthesis of 4,6-Diaryl-2-oxo(imino)-1,2-dihydropyridine-3- carbonitrile; A new scaffold for p38α MAP kinase inhibition Journal of Combinatorial Chemistry. 12: 559-565. PMID 20518551 DOI: 10.1021/Cc1000488 |
0.375 |
|
| 2010 |
Koch P, Laufer S. Unexpected reaction of 2-alkylsulfanylimidazoles to imidazol-2-ones: pyridinylimidazol-2-ones as novel potent p38alpha mitogen-activated protein kinase inhibitors. Journal of Medicinal Chemistry. 53: 4798-802. PMID 20481631 DOI: 10.1021/Jm100161Q |
0.364 |
|
| 2010 |
Dorn A, Schattel V, Laufer S. Design, synthesis and SAR of phenylamino-substituted 5,11-dihydro-dibenzo[a,d]cyclohepten-10-ones and 11H-dibenzo[b,f]oxepin-10-ones as p38 MAP kinase inhibitors Bioorganic and Medicinal Chemistry Letters. 20: 3074-3077. PMID 20418099 DOI: 10.1016/J.Bmcl.2010.03.107 |
0.362 |
|
| 2010 |
Munoz L, Ramsay EE, Manetsch M, Ge Q, Peifer C, Laufer S, Ammit AJ. Novel p38 MAPK inhibitor ML3403 has potent anti-inflammatory activity in airway smooth muscle. European Journal of Pharmacology. 635: 212-8. PMID 20226180 DOI: 10.1016/J.Ejphar.2010.02.037 |
0.339 |
|
| 2010 |
Munoz L, Selig R, Yeung YT, Peifer C, Hauser D, Laufer S. Fluorescence polarization binding assay to develop inhibitors of inactive p38α mitogen-activated protein kinase Analytical Biochemistry. 401: 125-133. PMID 20175985 DOI: 10.1016/J.Ab.2010.02.016 |
0.353 |
|
| 2010 |
Koch P, Jahns H, Schattel V, Goettert M, Laufer S. Pyridinylquinoxalines and pyridinylpyridopyrazines as lead compounds for novel p38 alpha mitogen-activated protein kinase inhibitors. Journal of Medicinal Chemistry. 53: 1128-37. PMID 20078117 DOI: 10.1021/Jm901392X |
0.394 |
|
| 2009 |
Jahns H, Koch P, Schollmeyer D, Laufer S. 1-[2-(Benzyl-amino)-4-pyrid-yl]-2-(4-fluoro-phen-yl)ethane-1,2-dione. Acta Crystallographica. Section E, Structure Reports Online. 65: o1451. PMID 21583289 DOI: 10.1107/S1600536809019801 |
0.312 |
|
| 2009 |
Koch P, Schollmeyer D, Laufer S. 4-[3-(4-Fluoro-phen-yl)quinoxalin-2-yl]-N-isopropyl-pyridin-2-amine. Acta Crystallographica. Section E, Structure Reports Online. 65: o1344. PMID 21583196 DOI: 10.1107/S1600536809018285 |
0.324 |
|
| 2009 |
Jahns H, Koch P, Schollmeyer D, Laufer S. 3-(4-Fluoro-phen-yl)-6-meth-oxy-2-(4-pyrid-yl)quinoxaline. Acta Crystallographica. Section E, Structure Reports Online. 65: o1626. PMID 21582893 DOI: 10.1107/S1600536809022119 |
0.309 |
|
| 2009 |
Koch P, Schollmeyer D, Laufer S. 4-[5-(4-Fluoro-phen-yl)-1H-imidazol-4-yl]pyridine. Acta Crystallographica. Section E, Structure Reports Online. 65: o573. PMID 21582228 DOI: 10.1107/S1600536809005650 |
0.322 |
|
| 2009 |
Abu Thaher B, Koch P, Schollmeyer D, Laufer S. 4-[2-(4-Fluoro-phen-yl)furan-3-yl]pyridine. Acta Crystallographica. Section E, Structure Reports Online. 65: o458. PMID 21582130 DOI: 10.1107/S1600536809003651 |
0.321 |
|
| 2009 |
Abu Thaher B, Koch P, Schollmeyer D, Laufer S. 4-[2-(4-Fluoro-phen-yl)-1H-pyrrol-3-yl]pyridine. Acta Crystallographica. Section E, Structure Reports Online. 65: o457. PMID 21582129 DOI: 10.1107/S160053680900364X |
0.323 |
|
| 2009 |
Selig R, Schollmeyer D, Stegmiller T, Albrecht W, Laufer S. (2Z)-2-Fluoro-N-{4-[5-(4-fluorophenyl)-2-methylsulfanyl-1H-imidazol-4-yl]-2-pyridyl}-3-phenylacrylamide Acta Crystallographica Section E-Structure Reports Online. 65. PMID 21578977 DOI: 10.1107/S1600536809051010 |
0.319 |
|
| 2009 |
Ziegler K, Schollmeyer D, Laufer S. N-{4-[4-(4-Fluoro-phen-yl)-1-(2-methoxy-ethyl)-2-methyl-sulfanyl-1H-imidazol-5-yl]-2-pyrid-yl}-2-methyl-3-phenyl-propionamide. Acta Crystallographica. Section E, Structure Reports Online. 65: o3128. PMID 21578851 DOI: 10.1107/S1600536809048661 |
0.329 |
|
| 2009 |
Koch P, Schollmeyer D, Laufer S. N-{4-[3-(4-Fluoro-phen-yl)pyrido[2,3-b]pyrazin-2-yl]-2-pyrid-yl}isopropyl-amine. Acta Crystallographica. Section E, Structure Reports Online. 65: o2557. PMID 21577998 DOI: 10.1107/S1600536809038173 |
0.328 |
|
| 2009 |
Koch P, Schollmeyer D, Laufer S. 3-(4-Fluoro-phen-yl)-2-(4-pyrid-yl)pyrido[2,3-b]pyrazine. Acta Crystallographica. Section E, Structure Reports Online. 65: o2546. PMID 21577988 DOI: 10.1107/S1600536809037970 |
0.317 |
|
| 2009 |
Koch P, Schollmeyer D, Laufer S. 2-(4-Fluoro-phen-yl)-3-(4-pyrid-yl)pyrido[2,3-b]pyrazine. Acta Crystallographica. Section E, Structure Reports Online. 65: o2512. PMID 21577959 DOI: 10.1107/S1600536809037295 |
0.309 |
|
| 2009 |
Cheeseright TJ, Holm M, Lehmann F, Luik S, Gottert M, Melville JL, Laufer S. Novel lead structures for p38 MAP kinase via FieldScreen virtual screening Journal of Medicinal Chemistry. 52: 4200-4209. PMID 19489590 DOI: 10.1021/Jm801399R |
0.382 |
|
| 2009 |
Abu Thaher B, Koch P, Schattel V, Laufer S. Role of the hydrogen bonding heteroatom-Lys53 interaction between the p38alpha mitogen-activated protein (MAP) kinase and pyridinyl-substituted 5-membered heterocyclic ring inhibitors. Journal of Medicinal Chemistry. 52: 2613-7. PMID 19301816 DOI: 10.1021/Jm801467H |
0.358 |
|
| 2009 |
Laufer S, Lehmann F. Investigations of SCIO-469-like compounds for the inhibition of p38 MAP kinase Bioorganic and Medicinal Chemistry Letters. 19: 1461-1464. PMID 19195885 DOI: 10.1016/J.Bmcl.2009.01.023 |
0.353 |
|
| 2009 |
Peifer C, Bühler S, Hauser D, Kinkel K, Totzke F, Schächtele C, Laufer S. Design, synthesis and characterization of N9/N7-substituted 6-aminopurines as VEGF-R and EGF-R inhibitors European Journal of Medicinal Chemistry. 44: 1788-1793. PMID 18524423 DOI: 10.1016/J.Ejmech.2008.04.012 |
0.307 |
|
| 2009 |
Laufer S, Ahrens G, Karcher S, Niess R, Hering J. Targeting Proteinkinases: The Selectivity Problem Scientia Pharmaceutica. 77: 165-165. DOI: 10.3797/Scipharm.Oephg.21.Pl-03 |
0.325 |
|
| 2008 |
Koch P, Schollmeyer D, Laufer S. tert-Butyl N-benzyl-N-(4-methyl-2-pyrid-yl)carbamate. Acta Crystallographica. Section E, Structure Reports Online. 64: o2222. PMID 21581077 DOI: 10.1107/S1600536808034491 |
0.322 |
|
| 2008 |
Koch P, Schollmeyer D, Laufer S. tert-Butyl N-benzyl-N-[4-(4-fluoro-benzoyl-meth-yl)-2-pyrid-yl]carbamate. Acta Crystallographica. Section E, Structure Reports Online. 64: o2221. PMID 21581076 DOI: 10.1107/S160053680803448X |
0.313 |
|
| 2008 |
Koch P, Schollmeyer D, Laufer S. tert-Butyl N-(4-methyl-2-pyrid-yl)-carbamate. Acta Crystallographica. Section E, Structure Reports Online. 64: o2216. PMID 21581073 DOI: 10.1107/S1600536808032327 |
0.327 |
|
| 2008 |
Koch P, Bäuerlein C, Schollmeyer D, Laufer S. Methyl 4-[5-(4-fluoro-phen-yl)-4-(pyridin-4-yl)-1H-imidazol-2-ylsulfan-yl]butanoate. Acta Crystallographica. Section E, Structure Reports Online. 64: o1183-4. PMID 21202826 DOI: 10.1107/S1600536808016000 |
0.389 |
|
| 2008 |
Koch P, Bäuerlein C, Jank H, Laufer S. Targeting the ribose and phosphate binding site of p38 mitogen-activated protein (MAP) kinase: Synthesis and biological testing of 2-alkylsulfanyl-, 4(5)-aryl-, 5(4)-heteroaryl-substituted imidazoles Journal of Medicinal Chemistry. 51: 5630-5640. PMID 18763757 DOI: 10.1021/Jm800373T |
0.369 |
|
| 2008 |
Laufer S, Greim C, Luik S, Ayoub SS, Dehner F. Human whole blood assay for rapid and routine testing of non-steroidal anti-inflammatory drugs (NSAIDs) on cyclo-oxygenase-2 activity. Inflammopharmacology. 16: 155-61. PMID 18759073 DOI: 10.1007/S10787-008-8007-X |
0.325 |
|
| 2008 |
Koeberle A, Siemoneit U, Bühring U, Northoff H, Laufer S, Albrecht W, Werz O. Licofelone Suppresses Prostaglandin E2 Formation by Interference with the Inducible Microsomal Prostaglandin E2 Synthase-1 Journal of Pharmacology and Experimental Therapeutics. 326: 975-982. PMID 18550688 DOI: 10.1124/Jpet.108.139444 |
0.344 |
|
| 2008 |
Peifer C, Selig R, Kinkel K, Ott D, Totzke F, Schächtele C, Heidenreich R, Röcken M, Schollmeyer D, Laufer S. Design, synthesis, and biological evaluation of novel 3-aryl-4-(1H-indole-3yl)-1,5-dihydro-2H-pyrrole-2-ones as vascular endothelial growth factor receptor (VEGF-R) inhibitors. Journal of Medicinal Chemistry. 51: 3814-24. PMID 18529047 DOI: 10.1021/Jm8001185 |
0.358 |
|
| 2008 |
Laufer S, Koch P. Towards the improvement of the synthesis of novel 4(5)-aryl-5(4)-heteroaryl-2-thio-substituted imidazoles and their p38 MAP kinase inhibitory activity. Organic & Biomolecular Chemistry. 6: 437-9. PMID 18219408 DOI: 10.1039/B717605H |
0.345 |
|
| 2008 |
Peifer C, Urich R, Schattel V, Abadleh M, Röttig M, Kohlbacher O, Laufer S. Implications for selectivity of 3,4-diarylquinolinones as p38αMAP kinase inhibitors Bioorganic & Medicinal Chemistry Letters. 18: 1431-1435. PMID 18207396 DOI: 10.1016/J.Bmcl.2007.12.073 |
0.345 |
|
| 2008 |
Tavolari S, Bonafè M, Marini M, Ferreri C, Bartolini G, Brighenti E, Manara S, Tomasi V, Laufer S, Guarnieri T. Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade. Carcinogenesis. 29: 371-380. PMID 18033773 DOI: 10.1093/Carcin/Bgm265 |
0.308 |
|
| 2008 |
Ospelt C, Kurowska-Stolarska M, Neidhart M, Michel BA, Gay RE, Laufer S, Gay S. The dual inhibitor of lipoxygenase and cyclooxygenase ML3000 decreases the expression of CXCR3 ligands. Annals of the Rheumatic Diseases. 67: 524-9. PMID 17666446 DOI: 10.1136/Ard.2007.071589 |
0.31 |
|
| 2008 |
Holm M, Schollmeyer D, Laufer S. 3-(2-Fluoro-phen-yl)-6-(phenoxy-meth-yl)-1,2,4-triazolo[3,4-b][1,3,4] thia-diazole Acta Crystallographica Section E: Structure Reports Online. 64. DOI: 10.1107/S1600536808003917 |
0.377 |
|
| 2008 |
Laufer S, Abu Thaher B, Koch P, Del Amo V, Knochel P. A Convenient Synthesis of 1-(4-Fluorophenyl)-2-(4-pyridyl)cyclopentene from Cyclopentanone Synthesis. 2008: 225-228. DOI: 10.1055/S-2007-1000855 |
0.375 |
|
| 2008 |
Holm M, Lehmann F, Laufer S. Emphasis on pharmaceutical research: Medical chemistry and molecular inhibiting mechanism of tyrosine kinase inhibitors Pharmazie in Unserer Zeit. 37: 382-392. DOI: 10.1002/Pauz.200800279 |
0.313 |
|
| 2007 |
Kammerer B, Scheible H, Albrecht W, Gleiter CH, Laufer S. Pharmacokinetics of ML3403 ({4-[5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenylethyl)-amine), a 4-Pyridinylimidazole-type p38 mitogen-activated protein kinase inhibitor. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 35: 875-83. PMID 17344341 DOI: 10.1124/Dmd.106.013409 |
0.372 |
|
| 2007 |
Peifer C, Kinkel K, Abadleh M, Schollmeyer D, Laufer S. From five- to six-membered rings: 3,4-diarylquinolinone as lead for novel p38MAP kinase inhibitors. Journal of Medicinal Chemistry. 50: 1213-1221. PMID 17323937 DOI: 10.1021/Jm061097O |
0.393 |
|
| 2007 |
Buehler S, Schollmeyer D, Hauser D, Laufer S, Peifer C. 2-(6-Meth-oxy-7H-purin-7-yl)-1-phenyl-ethanone monohydrate Acta Crystallographica Section E: Structure Reports Online. 63: o4154-o4155. DOI: 10.1107/S1600536807044212 |
0.384 |
|
| 2007 |
Thaher BA, Schollmeyer D, Laufer S. 2-(4-Fluoro-phen-yl)-1-(4-pyrid-yl)cyclo-pentan-1-ol Acta Crystallographica Section E: Structure Reports Online. 63. DOI: 10.1107/S1600536807034034 |
0.397 |
|
| 2007 |
Peifer C, Schollmeyer D, Tschertsche M, Laufer S. (2aRS,3RS,4aSR,6aRS,6bSR)-3-Hydroxy-2a,3,4a,6,6a,6b-hexahydro-1, 4-dioxacyclopenta-[cd]pentalen-2(5H)-one Acta Crystallographica Section E: Structure Reports Online. 63. DOI: 10.1107/S1600536807014717 |
0.312 |
|
| 2007 |
Peifer C, Schollmeyer D, Kinkel K, Laufer S. 3-(4-Fluorophenyl)-1-methyl-4-(4-pyridyl)quinolin-2(1H)-one Acta Crystallographica Section E: Structure Reports Online. 63. DOI: 10.1107/S1600536807014638 |
0.35 |
|
| 2007 |
Kinkel K, Laufer S, Schollmeyer D, Peifer C. 2,2-Dimethyl-N-[3-(3,4,5-trimethoxybenzoyl)-pyridin-4-yl]propanamide Acta Crystallographica Section E: Structure Reports Online. 63. DOI: 10.1107/S1600536807012500 |
0.316 |
|
| 2007 |
Peifer C, Schollmeyer D, Tschertsche M, Laufer S. Rac-(3E,3aR,6aR)-3-(Hydroxymethylene)-3,3a,6,6a-tetrahydro-2H-cyclopenta[b] furan-2-one Acta Crystallographica Section E: Structure Reports Online. 63. DOI: 10.1107/S1600536807009300 |
0.337 |
|
| 2007 |
Abadleh M, Peifer C, Kinkel K, Schollmeyer D, Laufer S. 4-[5-(4-Fluorophenyl)-3-isopropylisoxazol-4-yl]pyridin-2(1H)-one Acta Crystallographica Section E-Structure Reports Online. 63. DOI: 10.1107/S1600536807007933 |
0.372 |
|
| 2007 |
Peifer C, Ott D, Schollmeyer D, Laufer S. Ethyl (2,3-dihydro-1H,1′H-2,3′-biindol-1-yl)glyoxylate Acta Crystallographica Section E: Structure Reports Online. 63. DOI: 10.1107/S1600536807007660 |
0.315 |
|
| 2007 |
Peifer C, Tschertsche M, Schollmeyer D, Laufer S. (1aR,2aS,5aS,5bS)-perhydro-4H-oxireno[3,4]cyclopenta-[1,2-b]furan-4-one Acta Crystallographica Section E: Structure Reports Online. 63. DOI: 10.1107/S160053680700743X |
0.308 |
|
| 2007 |
Peifer C, Selig R, Schollmeyer D, Laufer S. N-{(Z)-2-[1-(triisopropylsilyl)-1H-indol-3-yl]-2-(triisopropylsilyloxy) vinyl}-2-(3,4,5-trimethoxy-phenyl)acetamide Acta Crystallographica Section E: Structure Reports Online. 63. DOI: 10.1107/S1600536807006514 |
0.333 |
|
| 2006 |
Peifer C, Krasowski A, Hämmerle N, Kohlbacher O, Dannhardt G, Totzke F, Schächtele C, Laufer S. Profile and Molecular Modeling of 3-(Indole-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-pyrrole-2,5dione (1) as a Highly Selective VEGF-R2/3 Inhibitor Journal of Medicinal Chemistry. 49: 7549-7553. PMID 17149885 DOI: 10.1021/Jm0609871 |
0.306 |
|
| 2006 |
Peifer C, Luik S, Thuma S, Herweh Y, Laufer S. Development and optimization of a non-radioactive JNK3 assay. Combinatorial Chemistry & High Throughput Screening. 9: 613-618. PMID 17017881 DOI: 10.2174/138620706778249721 |
0.355 |
|
| 2006 |
Laufer S, Linsenmaier S. Development of a microsphere-based p38α MAP kinase no-wash assay Journal of Biomolecular Screening. 11: 528-536. PMID 16760368 DOI: 10.1177/1087057106288187 |
0.323 |
|
| 2006 |
Peifer C, Wagner G, Laufer S. New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase Current Topics in Medicinal Chemistry. 6: 113-149. PMID 16454763 DOI: 10.2174/156802606775270323 |
0.578 |
|
| 2006 |
Wagner G, Laufer S. Small molecular anti-cytokine agents Medicinal Research Reviews. 26: 1-62. PMID 16283677 DOI: 10.1002/Med.20042 |
0.579 |
|
| 2006 |
Peifer C, Abadleh M, Schollmeyer D, Laufer S. 3,4-Bis(4-fluorophenyl)-1,2,5-oxadiazole 2-oxide Acta Crystallographica Section E: Structure Reports Online. 62. DOI: 10.1107/S1600536806040049 |
0.311 |
|
| 2006 |
Peifer C, Abadleh M, Schollmeyer D, Laufer S. 4-[3-(4-Fluorophenyl)-5-isopropylisoxazol-4-yl]-pyridine Acta Crystallographica Section E: Structure Reports Online. 62. DOI: 10.1107/S1600536806030467 |
0.352 |
|
| 2006 |
Peifer C, Abadleh M, Schollmeyer D, Laufer S. 4-[5-(4-Fluorophenyl)-3-isopropylisoxazol-4-yl]-pyridine Acta Crystallographica Section E: Structure Reports Online. 62. DOI: 10.1107/S1600536806029448 |
0.372 |
|
| 2006 |
Peifer C, Schollmeyer D, Selig R, Laufer S. 4-(4-fluorophenyl)-3-(4-pyridyl)quinolin-2(1H)-one Acta Crystallographica Section E: Structure Reports Online. 62. DOI: 10.1107/S1600536806020095 |
0.301 |
|
| 2006 |
Peifer C, Schollmeyer D, Laudage S, Laufer S. 3-(4-Fluorophenyl)-4-(4-pyridyl)quinolin-2(1H)-one Acta Crystallographica Section E: Structure Reports Online. 62. DOI: 10.1107/S1600536806018885 |
0.304 |
|
| 2006 |
Wagner G, Laufer S. Small Molecular anti-Cytokine Agents Cheminform. 37. DOI: 10.1002/CHIN.200619241 |
0.47 |
|
| 2005 |
Ulbrich H, Soehnlein O, Xie X, Eriksson EE, Lindbom L, Albrecht W, Laufer S, Dannhardt G. Licofelone, a novel 5-LOX/COX-inhibitor, attenuates leukocyte rolling and adhesion on endothelium under flow. Biochemical Pharmacology. 70: 30-36. PMID 15894291 DOI: 10.1016/J.Bcp.2005.03.031 |
0.341 |
|
| 2004 |
Laufer S. Osteoarthritis therapy - Are there still unmet needs? Rheumatology. 43. PMID 14752170 DOI: 10.1093/Rheumatology/Keh103 |
0.31 |
|
| 2003 |
Laufer SA, Wagner GK, Kotschenreuther DA, Albrecht W. Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. Journal of Medicinal Chemistry. 46: 3230-44. PMID 12852754 DOI: 10.1021/Jm030766K |
0.54 |
|
| 2003 |
Wagner GK, Kotschenreuther D, Zimmermann W, Laufer SA. Identification of regioisomers in a series of N-substituted pyridin-4-yl imidazole derivatives by regiospecific synthesis, GC/MS, and 1H NMR. The Journal of Organic Chemistry. 68: 4527-30. PMID 12762762 DOI: 10.1021/Jo026619W |
0.549 |
|
| 2002 |
Laufer S, Greim C, Bertsche T. An in-vitro screening assay for the detection of inhibitors of proinflammatory cytokine synthesis: A useful tool for the development of new antiarthritic and disease modifying drugs Osteoarthritis and Cartilage. 10: 961-967. PMID 12464556 DOI: 10.1053/Joca.2002.0851 |
0.353 |
|
| 2002 |
Kartasasmita RE, Laufer S, Lehmann J. NO-donors (VII [1]): Synthesis and cyclooxygenase inhibitory properties of N- and S-nitrooxypivaloyl-cysteine derivatives of naproxen - A novel type of NO-NSAID Archiv Der Pharmazie. 335: 363-366. PMID 12397619 DOI: 10.1002/1521-4184(200211)335:8<363::Aid-Ardp363>3.0.Co;2-S |
0.324 |
|
| 2002 |
Laufer SA, Striegel HG, Wagner GK. Imidazole inhibitors of cytokine release: probing substituents in the 2 position. Journal of Medicinal Chemistry. 45: 4695-705. PMID 12361396 DOI: 10.1021/Jm020873Z |
0.516 |
|
| 2002 |
Laufer S, Wagner G, Kotschenreuther D. Ones, thiones, and N-oxides: An eercise in imidazole chemistry Angewandte Chemie - International Edition. 41: 2290-2293. PMID 12203569 DOI: 10.1002/1521-3773(20020703)41:13<2290::Aid-Anie2290>3.0.Co;2-R |
0.566 |
|
| 2002 |
Paredes Y, Massicotte F, Pelletier JP, Martel-Pelletier J, Laufer S, Lajeunesse D. Study of the role of leukotriene B()4 in abnormal function of human subchondral osteoarthritis osteoblasts: effects of cyclooxygenase and/or 5-lipoxygenase inhibition. Arthritis and Rheumatism. 46: 1804-12. PMID 12124864 DOI: 10.1002/Art.10357 |
0.313 |
|
| 2002 |
Laufer SA, Wagner GK. From imidazoles to pyrimidines: New inhibitors of cytokine release Journal of Medicinal Chemistry. 45: 2733-2740. PMID 12061876 DOI: 10.1021/Jm011098A |
0.538 |
|
| 2002 |
Klaas CA, Wagner G, Laufer S, Sosa S, Della Loggia R, Bomme U, Pahl HL, Merfort I. Studies on the anti-inflammatory activity of phytopharmaceuticals prepared from Arnica flowers. Planta Medica. 68: 385-91. PMID 12058311 DOI: 10.1055/S-2002-32067 |
0.553 |
|
| 2001 |
Celotti F, Laufer S. Anti-inflammatory drugs: New multitarget compounds to face an old problem. The dual inhibition concept Pharmacological Research. 43: 429-436. PMID 11394934 DOI: 10.1006/Phrs.2000.0784 |
0.339 |
|
| 2001 |
Abadi AH, Laufer S, Lehmann J. Synthesis and cyclooxygenase inhibitory properties of novel (+) 2-(6-methoxy-2-naphthyl)propanoic acid (naproxene) derivatives Archiv Der Pharmazie. 334: 104-106. PMID 11315336 DOI: 10.1002/1521-4184(200103)334:3<104::Aid-Ardp104>3.0.Co;2-R |
0.32 |
|
| 2001 |
Tries S, Laufer S. The pharmacological profile of ML3000: A new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase Inflammopharmacology. 9: 113-124. DOI: 10.1163/156856001300248380 |
0.354 |
|
| 2001 |
Laufer S. Discovery and development of ML3000 Inflammopharmacology. 9: 101-112. DOI: 10.1163/156856001300248371 |
0.342 |
|
| 1999 |
Laufer S, Zechmeister P, Klein T. Development of an in-vitro test system for the evaluation of cyclooxygenase-2 inhibitors Inflammation Research. 48: 133-138. PMID 10219655 DOI: 10.1007/S000110050436 |
0.324 |
|
| 1997 |
Abraham WM, Laufer S, Tries S. The effects of ML 3000 on antigen-induced responses in sheep Pulmonary Pharmacology and Therapeutics. 10: 167-173. PMID 9514627 DOI: 10.1006/Pupt.1997.0090 |
0.305 |
|
| 1997 |
Laufer S, Striegel H, Neher K, Zechmeister P, Donat C, Stolingwa K, Baur S, Tries S, Kammermeier T, Dannhardt G, Kiefer W. Synthesis and Evaluation of a Novel Series of Pyrrolizine Derivatives as Dual Cyclooxygenase‐1 and 5‐Lipoxygenase Inhibitors Archiv Der Pharmazie. 330: 307-312. PMID 9396390 DOI: 10.1002/Ardp.19973300908 |
0.321 |
|
| 1994 |
Laufer S, Tries S, Augustin J. P59 Diarylpyrrolizines; dual inhibitors of CO and 5-LO European Journal of Pharmaceutical Sciences. 2: 133. DOI: 10.1016/0928-0987(94)90232-1 |
0.307 |
|
| 1991 |
Dannhardt G, Dominiak P, Laufer S. 5-(β-Aminoethyl)aminoisoxazoles with hypertensive activity: Synthesis and screening of isoxazolo-pyrazines and isoxazolo-diazepines Archiv Der Pharmazie. 324: 141-148. PMID 1859249 DOI: 10.1002/Ardp.19913240303 |
0.323 |
|
| 1990 |
Dannhardt G, Dominiak P, Laufer S. 5-(β-Aminoethyl)aminoisoxazoles with hypertensive activity: Synthesis and screening of derivatives with partially rigid C-5 side chains and heterocycles at the ω-position, respectively Archiv Der Pharmazie. 323: 571-578. PMID 2288479 DOI: 10.1002/Ardp.19903230904 |
0.309 |
|
| 1989 |
Dannhardt G, Laufer S. 5-(2-Aminoethyl)-3-aryl-5-phenylaminoisoxazole durch Ringtransformation von 2-Phenacylidenimidazolidinen Synthesis. 1989: 12-15. DOI: 10.1055/S-1989-27131 |
0.314 |
|
| Show low-probability matches. |